Random glucose GWAS in 493,036 individuals provides insights into diabetes pathophysiology, complications and treatment stratification - Lagou, Vasiliki; Jiang, Longda; Ulrich, Anna; Zudina, Liudmila; González, Karla Sofia Gutiérrez; Balkhiyarova, Zhanna; Faggian, Alessia; Chen, Shiqian; Todorov, Petar; Sharapov, Sodbo; David, Alessia; Marullo, Letizia; et al. (medRxiv, 2021)
Homeostatic control of blood glucose requires different physiological responses in the fasting and post-prandial states. We reasoned that glucose measurements under non-standardised conditions (random glucose; RG) may capture diverse glucoregulatory processes more effectively than previous genome-wide association studies (GWAS) of fasting glycaemia or after standardised glucose loads. Through GWAS meta-analysis of RG in 493,036 individuals without diabetes of diverse ethnicities we identified 128 associated loci represented by 162 distinct signals, including 14 with sex-dimorphic effects, 9 discovered through trans-ethnic analysis, and 70 novel signals for glycaemic traits. Novel RG loci were particularly enriched in expression in the ileum and colon, indicating a prominent role for the gastrointestinal tract in the control of blood glucose. Functional studies and molecular dynamics simulations of coding variants of GLP1R, a well-established type 2 diabetes treatment target, provided a genetic framework for optimal selection of GLP-1R agonist therapy. We also provided new evidence from Mendelian randomisation that lung function is modulated by blood glucose and that pulmonary dysfunction is a diabetes complication. Thus, our approach based on RG GWAS provided wide-ranging insights into the biology of glucose regulation, diabetes complications and the potential for treatment stratification.Competing Interest StatementAlejandra Tomas has received grant funding from Sun Pharmaceuticals. Ivan R Corrêa, Jr is an employee of New England Biolabs, Inc., a manufacturer and vendor of reagents for life science research. Mark J Caulfield is Chief Scientist for Genomics England, a UK Government company. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Mark McCarthy has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, MMcC is an employee of Genentech, and a holder of Roche stock. Patrick M Sexton receives grant funding from Laboratoires Servier. Toby Johnson is now a GSK employee. Yurii S Aulchenko is owner of Maatschap PolyOmica and PolyKnomics BV, private organizations providing services, research and development in the field of computational and statistical, quantitative and computational (gen)omics. Funding StatementAcknowledgements Airwave: The Airwave Health Monitoring Study was funded by the UK Home Office (780- TETRA, 2003-2018) and is currently funded by the MRC and ESRC (MR/R023484/1) with additional funding from the NIHR Imperial College Biomedical Research Centre (BRC) in collaboration with Imperial College NHS Healthcare Trust. We thank all Airwave participants for their contribution to the study.Paul Elliott acknowledges support from the MRC and PHE (MR/L01341X/1, 812 2014-2019) and currently from the MRC for the MRC Centre for Environment and Health 813 (MR/S019669/1). Paul Elliott and Ioanna Tzoulaki are supported by the UK Dementia Research Institute which receives funding from UK DRI Ltd funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. Paul Elliott is associate director of the Health Data Research UK London funded by a consortium led by the UK Medical Research Council. BRIGHT: This work was funded by the Medical Research Council of Great Britain (grant number: G9521010D). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. This work formed part of the research themes contributing to the translational research portfolio for the NIHR Barts Cardiovascular Biomedical Research Centre. The funders had no role in study design, data collection and analysis. deCODE: We thank participants in deCODE genetic studies whose contribution made this work possible. EMIL: EMIL-Cohort, a population-based cohort; the study was approved by the ethical committee of the Chamber of Physicians Baden-Württemberg in the year 2002 (Registration Number 133-02; dates 05.09.2002 and 24.09.2002). We thank Silke Rosinger, Simone Claudi-Boehm, Rosina Sing, Sabine Schilling and Angelika Kurkhaus for technical support. EPIC-Norfolk: The EPIC-Norfolk study (https://doi.org/10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). The genetics work in the EPIC-Norfolk study was funded by the Medical Research Council (MC_PC_13048). We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. FINRISK87: Support for FUSION was provided by NIH grants R01-DK062370 (to M.B.), R01-DK072193 (to K.L.M.), and intramural project number 1Z01-HG000024 (to F.S.C.). Genome-wide genotyping was conducted by the Johns Hopkins University Genetic Resources Core Facility SNP Center at the Center for Inherited Disease Research (CIDR), with support from CIDR NIH contract no. N01-HG-65403. Framingham Heart Study: Also supported by National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) U01/UM1 DK078616 to Dr. Meigs HUNT2/Tromson: The Nord-Trøndelag Health Study (the HUNT study) is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. University of Tromsø, Norwegian Research Council (project number 185764). InterAct: We thank all EPIC participants and staff and the InterAct Consortium members for their contributions to the study. The InterAct project received funding from the European Union (Integrated Project LSHM-CT-2006-037197 in the Framework Programme 6 of the European Community). We thank staff from the technical, field epidemiology and data teams of the Medical Research Council Epidemiology Unit in Cambridge, UK, for carrying out sample preparation, DNA provision and quality control, genotyping and data handling work. KORA F3: The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München–German Research Center for Environment and Health, which is funded by the German Federal Ministry of Education and Research and by the state of Bavaria. Furthermore, part of this work was supported by the German National Genome Research Network (NGFN) and the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. Brisbane Adolescent Twin Study / SSAGA-NAG adult cohort: Genotyping and phenotyping were supported by the Australian National Health and Medical Research Council (389891, 389892, 496739), the EU 5th Framework Programme GenomEUtwin Project (QLG2-CT-2002-01254) and the U.S. National Institutes of Health (AA07535, AA13320, AA13321, AA13326, AA14041, DA12854). B.B. and G.W.M. are supported by National Health and Medical Research Council (NHMRC) Fellowship Schemes. Participants gave informed consent and the studies were approved by appropriate institutional review boards. PPP-Botnia/Malmö Diet Cancer: Emma Ahlqvist was funded by grants from the Swedish Research Council (2017-02688, 2020-02191). PROCARDIS: PROCARDIS was supported by the European Community Sixth Framework Program (LSHM-CT- 2007-037273), AstraZeneca, the British Heart Foundation, the Wellcome Trust (Contract No. 075491/Z/04), the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Swedish Heart-Lung Foundation, the Torsten and Ragnar Söderberg Foundation, the Strategic Cardiovascular and Diabetes Programs of Karolinska Institutet and Stockholm County Council, the Foundation for Strategic Research and the Stockholm County Council. Ethical permission was granted by the local ethical board for each centre. Anuj Goel has received support from the BHF, European Commission [LSHM-CT- 2007-037273, HEALTH-F2-2013-601456] and TriPartite Immunometabolism Consortium [TrIC]- NovoNordisk Foundation [NNF15CC0018486]. Hugh Watkins has received support from Wellcome Trust core awards (090532/Z/09/Z, 203141/Z/16/Z) and is member of the Oxford BHF Centre for Research Excellence (RE/13/1/30181). Rona J Strawbridge is supported by a UKRI Innovation-HDR-UK Fellowship (MR/S003061/1). Rotterdam Study: The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The Section of Endocrinology and Investigative Medicine is funded by grants from the MRC, BBSRC, NIHR, and is supported by the NIHR Biomedical Research Centre Funding Scheme. The views expressed are those of the author(s) and not necessarily those of the any of the funders, the NHS, the NIHR or the Department of Health. UK Biobank: We thank UK Biobank for data availability, project number 37685. Personal support: Marika A Kaakinen, Anna Ulrich, Zhanna Balkhiyarova and Inga Prokopenko are in part funded by the European Union's Horizon 2020 research and innovation programme LONGITOOLS, H2020-SC1-2019-874739. Marika A Kaakinen is also funded by the European Foundation for the Study of Diabetes (EFSD) Albert Renold Travel Fellowship. Vanderbilt: The samples and/or dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10OD017985 and S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/". Personal support: NIH Grants R01 HL146588 and R01 HL146588-01S1. Individual acknowledgements: Alejandra Tomas was supported by MRC project grant MR/R010676/1 and grants from Diabetes UK and the European Federation for the Study of Diabetes. Alessia David is funded by Wellcome Trust grant 104955/Z/14/Z. Ben Jones is supported by an Imperial Post-CCT Post-Doctoral Fellowship, MRC project grant MR/R010676/1, and grants from the European Federation for the Study of Diabetes, Academy of Medical Sciences, Imperial NIHR Biomedical Research Centre, Engineering and Physical Sciences Research Council, Society for Endocrinology and British Society for Neuroendocrinology. Christopher Reynolds is a Royal Society Industry Fellow. Inês Barroso was funded by an "Expanding excellence in England" award from Research England. Inga Prokopenko is funded by the World Cancer Research Fund (WCRF UK) and World Cancer Research Fund International (2017/1641), the Wellcome Trust (WT205915), the European Union's Horizon 2020 research and innovation programme (DYNAhealth, project number 633595) the LONGITOOLS, H2020-SC1-2019-874739 and the Royal Society (IEC\R2\181075). Mark McCarthy was a Wellcome Investigator and an NIHR Senior Investigator (Niddk. U01-DK105535, Wellcome: 090532, 098381, 106130, 203141, 212259). Patrick M Sexton and Denise Wootten: The work was supported by NHMRC Ideas #1184726 and NHMRC program grant #1150083. Patrick M Sexton is a NHMRC Senior Principal Research Fellow (#1154434) and Denise Wootten is an NHMRC Senior Research Fellow (#1155302). Vasiliki Lagou was supported by a fellowship from the Research Foundation-Flanders (FWO). Victoria Salem is the recipient of a Diabetes UK Harry Keen Clinician Scientist Fellowship. Sharapov Sodbo was supported by a grant from the Russian Science Foundation (RSF) No. 19-15-00115. Tricia M Tan acknowledges support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) Funding Scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North West - Haydock Research Ethics Committee, UKAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics for RG analyses presented in this manuscript will be deposited on the MAGIC website and will be also be available through the NHGRI-EBI GWAS Catalog. https://www.magicinvestigators.org/downloads/ https://www.ebi.ac.uk/gwas/downloads/summary-statistics